Company Monitoring Page for Incyte

latest headlines for company on cafepharma

We don’t know when (exactly) Lilly will announce the FDA’s baricitinib decision, but watch out for the looming pricing squabble
Endpoints
Thu, 04/13/17 - 11:48 am
Tags:
Eli Lilly, FDA, baricitinib, drug pricing, Incyte
3 Big Drugmakers Most Likely to Buy Incyte
Motley Fool
Wed, 04/12/17 - 11:57 am
Tags:
Incyte, M&A, Gilead Sciences, Amgen, Bristol-Myers Squibb
Does Incyte Have The Best Cancer Portfolio Among Mid-Cap Biotechs?
Barron's
Tue, 04/11/17 - 10:07 am
Tags:
Incyte, epacadostat, olumiant, Jakafi, immuno-oncology
Would Gilead Sciences Make This Staggeringly Audacious Move?
Motley Fool
Sun, 04/9/17 - 12:27 pm
Tags:
Gilead Sciences, M&A, Celgene, Incyte
Racing in lung cancer again (or still), Merck and BMS expand Incyte combo trials
Fierce Pharma
Tue, 04/4/17 - 11:10 pm
Tags:
Merck, Bristol-Myers Squibb, Incyte, Keytruda, Opdivo, non-small cell lung cancer
4 Drug Stocks With Big News Coming in April
Motley Fool
Tue, 04/4/17 - 12:11 am
Tags:
Neurocrine, Incyte, Eli Lilly, Biomarin, Ingrezza, baricitinib, Brineura
Merck, Incyte Expand Cancer Collaboration
Barron's
Fri, 03/31/17 - 10:00 pm
Tags:
Merck, Incyte, epacadostat, Keytruda, melanoma
Gilead Sciences: Is an Incyte Deal ‘Reasonable’?
Barron's
Mon, 03/13/17 - 11:26 am
Tags:
Gilead Sciences, Incyte, M&A
Tapping into the rare disease market
BioPharma Dive
Fri, 03/10/17 - 09:00 pm
Tags:
Rare Diseases, Incyte, Horizon Pharma, Lundbeck
Incyte tops Street 4Q forecasts
Yahoo/AP
Tue, 02/14/17 - 12:09 pm
Tags:
Incyte, earnings
Forget Incyte: Gilead Sciences Would Be Better Off Buying This Company
Motley Fool
Wed, 01/25/17 - 09:53 am
Tags:
Gilead Sciences, Incyte, M&A, Galapagos
FDA delays decision on Lilly and Incyte's arthritis drug
BioPharma Dive
Tue, 01/17/17 - 11:04 am
Tags:
FDA, Eli Lilly, Incyte, rheumatoid arthritis, baricitinib
What Were Incyte’s Revenue Streams in 3Q16?
Market Realist
Sat, 01/7/17 - 12:38 pm
Tags:
Incyte, Jakafi, Iclusig
Biotech Investing: 3 Bold Predictions for 2017
Motley Fool
Fri, 01/6/17 - 09:47 am
Tags:
biotech, Incyte, Biogen, Biomarin, Gilead Sciences, Illumina
Biotech Stocks: What to Watch in 2017
Motley Fool
Tue, 01/3/17 - 10:02 am
Tags:
biotech, M&A, drug launches, Gilead Sciences, Incyte, Spinraza, Biogen, Ionis Pharmaceuticals, Amgen, Regeneron, Sanofi
The Most Likely Incyte Acquisition Deal for 2017?
Motley Fool
Sat, 12/24/16 - 12:11 pm
Tags:
M&A, Incyte, Gilead Sciences, Lilly, Novartis, Agenus
Incyte puts up $200M in bispecifics deal with Merus
BioPharma Dive
Thu, 12/22/16 - 10:21 am
Tags:
Incyte, Merus, bispecific antibodies
Gilead Fails to Beat Incyte’s Jakafi Drug
Investopedia
Sat, 11/19/16 - 11:32 am
Tags:
Gilead Sciences, Jakafi, Incyte, momelotinib, myelofibrosis
Should Gilead Sciences Purchase Incyte?
Seeking Alpha
Fri, 11/18/16 - 10:02 am
Tags:
Gilead Sciences, Incyte, M&A
3 Biotechs Most Likely to Be Acquired
Motley Fool
Tue, 10/11/16 - 09:45 pm
Tags:
biotech, M&A, Incyte, Biomarin, Biogen

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.